For decades, Medical Affairs (MA) was viewed primarily as a scientific support function — responsible for providing accurate medical information, responding to healthcare provider inquiries, and ensuring compliance. But in today’s rapidly evolving healthcare environment, MA has emerged as a strategic business partner, shaping how therapies are introduced, adopted, and optimized for patient benefit (Silva et al., 2024).

The Expanding Role of Medical Affairs

Modern MA teams work at the intersection of clinical development, regulatory affairs, market access, and commercial strategy. This shift is driven by:

  • Increasingly complex therapies — Advanced biologics, cell and gene therapies, and precision medicines require nuanced scientific communication to diverse stakeholders.
  • Demand for evidence beyond regulatory approval — Payers and health systems now require robust real-world evidence (RWE) to support reimbursement and formulary inclusion.
  • Heightened patient engagement — Patients are more involved in treatment decisions, necessitating patient-friendly communication and shared decision-making resources.

Real-Life Applicability: The Launch of a Novel Oncology Therapy

Consider a company preparing to launch a breakthrough oncology drug for a rare biomarker-defined cancer. The MA team’s involvement spans the full product life cycle:

  • Pre-launch — Gathering insights from key opinion leaders (KOLs) and patient advocacy groups to shape trial endpoints and ensure clinical relevance.
  • Launch phase — Training field medical teams to clearly explain biomarker science and help healthcare providers integrate testing into clinical pathways.
  • Post-launch — Designing and executing RWE studies to demonstrate long-term benefits, collaborating with payers on reimbursement strategies, and monitoring safety through pharmacovigilance.

In this example, MA is not simply a messenger — it is a strategic architect, ensuring that scientific, clinical, and economic narratives align to deliver patient value and secure market success.

The GMDP Academy Connection

To prepare professionals for this expanded role, the GMDP Academy’s Module 6: Medical Affairs as a Strategic Business Partner equips participants to integrate clinical evidence, health economics, and market access considerations into unified strategies (GMDP Academy, 2025/2026). Delivered in partnership with King’s College London as part of the globally recognized Certification in Medicines Development (CMD), this six-week module also develops the skills to:

  • Collaborate effectively across R&D, regulatory, and commercial teams.
  • Leverage digital tools and analytics for stronger stakeholder engagement.
  • Build compelling, evidence-based value propositions tailored to decision-makers.

Orientation for Module 6 begins August 25, 2025, and seats are limited. By joining this cohort, you’ll gain the competencies to position Medical Affairs as a true driver of both patient access and organizational success.

👉 Secure your place today: https://info.gmdpacademy.org/gmdpapplication

References

GMDP Academy. (2025/2026). GMDP Academy course catalog. https://info.gmdpacademy.org/course-catalog

Silva, H., Stonier, P., Chopra, P., Coots, J., Criscuolo, D., Guptha, S., Jones, S., Kerpel-Fronius, S., Kesselring, G., Luria, X., Morgan, D., Power, E., Salek, S., Silva, G., Suto, T., Thakker, K., & Vandenbroucke, P. (2024). Blended e-learning and certification for medicines development professionals: Results of a 7-year collaboration between King’s College London and the GMDP Academy, New York. Frontiers in Pharmacology, 15, 1417036. https://doi.org/10.3389/fphar.2024.1417036

Disclaimers

  • The material in these reviews is from various public open-access sources, meant for educational and informational purposes only
  • Any personal opinions expressed are those of only the author(s) and are not intended to represent the position of any organization(s)
  • No official support by any organization(s) has been provided or should be inferred